Preferred Label : Cevidoplenib;
NCIt definition : An orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory
and immunomodulating activities. Upon oral administration, cevidoplenib binds to and
inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated
signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural
killer (NK) cells and B-cells. This leads to the inhibition of the activation of these
inflammatory cells, and the related inflammatory responses and tissue damage. SYK,
a non-receptor cytoplasmic protein tyrosine kinase widely expressed in hematopoietic
cells, plays a key role in Fc receptor and B-cell receptor signaling in inflammatory
cells. It is involved in coupling activated immunoreceptors, such as Fc receptors
and B-cell receptors, to signal downstream events that mediate diverse cellular responses,
including proliferation, differentiation, and phagocytosis, which are important for
allergic and antibody-mediated immune diseases such as immune thrombocytopenia (ITP).;
UNII : 3N3H8BX897;
InChIKey : YCZUBLQESBVOSH-IBGZPJMESA-N;
CAS number : 1703788-21-9;
Molecule name : SKI-O-592; SKI O 592;
NCI Metathesaurus CUI : CL971935;
Origin ID : C166686;
UMLS CUI : C5238087;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_salt_form
- has_target
- is_free_acid_or_base_form_of
